Independent · non-commercial · publishes on a quarterly cycle|Current cycle 2026 Q3
Methodology|Interests|Funding|Corrections
Compound Evidence InstituteEvidence synthesis · established 2023Graded assessments of compounds, trials, methods and supply
Document set current to 30 July 2026
Trial register facet

Trial records reported in 2024 — page 3

51 records with a recorded report or completion year of 2024.

Showing 0 records on this page

Records

51 documents · page 3 of 3

Table 1. Trial records on this page. The table sorts on any column and filters on the controls above; both operate on the records shown on this page only.

RecordCompoundPhaseStatusDesignRandomisedYearCertainty
SYNERGY-NASH-BODY-COMPprogramme recordTirzepatidePhase 2ReportedRandomised, double-blind, placebo-controlled—2024Very low
SYNERGY-NASH-QOLprogramme recordTirzepatidePhase 2ReportedRandomised, double-blind, placebo-controlled—2024Very low
SYNERGY-NASH-REGIONAL-CNprogramme recordTirzepatidePhase 3ReportedRandomised, double-blind, placebo-controlled—2024Very low

page 3 of 3

Nothing published by the Institute is medical advice, a diagnosis, a prescription, a treatment recommendation or a purchasing recommendation. Compounds supplied for research use are not approved for human or veterinary use in any jurisdiction, and a favourable analytical assessment of a supplier is not a statement that any product is safe or effective. The Institute publishes certainty ratings and never recommendations. No telephone number, messaging handle or ordering channel appears anywhere on this site.